Here is a review of the effectiveness of fidaxomicin vs vancomycin for CDI treatment in populations with immunocompromised conditions.
Alex Peterson-Weber, PharmD
Advertisement
Peterson-Weber is a PGY2 infectious diseases pharmacy resident at Beth Israel Deaconess Medical Center in Boston, Massachusetts. Peterson-Weber is a member of the Society of Infectious Diseases Pharmacists.
Articles by Alex Peterson-Weber, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contagion Live
1
Phase 3 Trial Confirms Superior Efficacy of Oral Pritelivir for Refractory HSV in Immunocompromised Patients
2
Invivyd Announces FDA Clearance of IND Application for VYD2311 and Advancement of REVOLUTION Clinical Program
3
Top Infectious Disease News Stories Week of October 11-October 17
4
